Morning, I’m Louise Moon from Bloomberg UK’s breaking news team, bringing you up to speed on today’s top business stories. Hoping for a shot of energy, GSK is piling $10.6 billion into its oncology drive. The London-listed blue chip stock agreed to buy Nuvalent, a Massachusetts-based clinical stage biopharma firm, in one of its largest ever deals. That’s $124 per share in cash, marking a 40% premi...
Morning, I’m Louise Moon from Bloomberg UK’s breaking news team, bringing you up to speed on today’s top business stories. Hoping for a shot of energy, GSK is piling $10.6 billion into its oncology drive. The London-listed blue chip stock agreed to buy Nuvalent, a Massachusetts-based clinical stage biopharma firm, in one of its largest ever deals. That’s $124 per share in cash, marking a 40% premium to Nuvalent’s last closing price. It’s also the first major deal under GSK CEO Luke Miels, who joined earlier this year. And a significant step in his attempt to revitalise the company and bolster its pipeline amid investor fears about the drugs GSK has in development. The pharma giant isn’t known for risk-taking. Shares dipped at open, suggesting investor concerns haven’t yet quite been cured. What’s your take? Ping me on X , LinkedIn or drop me an email at lmoon13@bloomberg.net. Oh, and do subscribe to Bloomberg.com for unlimited access to trusted business journalism on the UK, and beyond. What We’re Watching Two big housebuilders flashed some warning signs this morning. Bellway noted moderated demand as mortgage rates rose, higher building cost material inflation and said the outlook is uncertain. Meanwhile, peer MJ Gleeson now expects pretax profit to miss expectations due to a delay in a land sales. Fevertree seems to be reaping the benefits of its US partnership with Molson Coors, and push into soft drinks. The premium tonic maker reiterated guidance, extended buybacks by £30 million and said it’s well hedged from a cost perspective amid the geopolitical dramas. Shares rose 7%. Hiring from abroad just got easier for “scale-up” firms in the digital and tech, life sciences, and clean energy sectors. The government plans to reimburse visa fees incurred from recruiting overseas talent in attempt to make the UK a more attractive place for tech companies (and fend off criticism that its policy changes have been detrimental). Plus, Bloomberg analysis shows Brexit may have...
We have selected seven stories from the SCMP’s coverage of Asia over the past week that resonated with our readers and shed light on topical issues. If you would like to see more of our reporting, please consider subscribing. 1. At least 35 dead, 200 injured, after magnitude 7.8 quake hits Philippines At least 35 people were killed and more than 200 injured after a magnitude 7.8 earthquake struck ...
We have selected seven stories from the SCMP’s coverage of Asia over the past week that resonated with our readers and shed light on topical issues. If you would like to see more of our reporting, please consider subscribing. 1. At least 35 dead, 200 injured, after magnitude 7.8 quake hits Philippines At least 35 people were killed and more than 200 injured after a magnitude 7.8 earthquake struck the southern Philippines on Monday, toppling buildings, setting off landslides and sending panicked...
GSK agreed to buy Nuvalent in a deal valued at $10.6 billion, adding a biotech firm that’s developing treatments for lung cancer as the British pharmaceutical company seeks to rebuild its oncology franchise. Sam Fazeli of Bloomberg Intelligence has more. (Source: Bloomberg)
GSK agreed to buy Nuvalent in a deal valued at $10.6 billion, adding a biotech firm that’s developing treatments for lung cancer as the British pharmaceutical company seeks to rebuild its oncology franchise. Sam Fazeli of Bloomberg Intelligence has more. (Source: Bloomberg)
Vachilavit Sanameang/iStock via Getty Images Fund Highlights Seeks a high level of income consistent with reasonable risk by investing primarily in income producing securities Primarily invests in investment grade corporate bonds, high yield corporate bonds, preferred stocks, U.S. municipal bonds and U.S. Treasuries Actively manages the portfolio by rotating among asset classes and tactically hedg...
Vachilavit Sanameang/iStock via Getty Images Fund Highlights Seeks a high level of income consistent with reasonable risk by investing primarily in income producing securities Primarily invests in investment grade corporate bonds, high yield corporate bonds, preferred stocks, U.S. municipal bonds and U.S. Treasuries Actively manages the portfolio by rotating among asset classes and tactically hedging during various interest rate and market environments Seeks to identify relative value across asset classes and capture opportunities primarily within the corporate, U.S. Treasury, municipal and preferred security markets Analyzes and targets the portfolio's level of risk and interest rate sensitivity Selects individual positions based on security credit metrics and structures Focuses on liquid securities with transparent pricing and actively-traded capital structures Market Recap Both U.S. equities and fixed income posted negative returns in the first quarter of 2026. Geopolitical tensions in Iran drove volatility, as disruptions to oil exports through the Strait of Hormuz raised concerns around global energy supply and stagflation. The Federal Reserve (Fed) held rates steady in January and March, keeping the upper bound of the federal funds rate at 3.75%, citing uncertainty around inflation and economic impacts. Labor markets showed mixed signals, with unemployment at 4.3% in February (down from 4.5% in December) and nonfarm payrolls declining modestly overall versus fourth quarter 2025. Meanwhile, core PCE rose to 3.1% year-over-year in February (from 2.8% in December), and WTI crude surged from $57 to $101, adding inflationary pressure. The Fed reiterated a data-dependent stance, with markets pricing in only a low-to-moderate probability of rate cuts in 2026, consistent with the March dot plot median projection of 3.375%. Fixed income returns were negative. The Bloomberg U.S. Aggregate Bond Index declined -0.05%, investment grade (IG) corporates fell -0.54%, and pref...
“Bloomberg: The China Show” is your definitive source for news and analysis on the world's second-biggest economy. From politics and policy to tech and trends, Yvonne Man and Stephen Engle give global investors unique insight, delivering in-depth discussions with the newsmakers who matter. (Source: Bloomberg)
“Bloomberg: The China Show” is your definitive source for news and analysis on the world's second-biggest economy. From politics and policy to tech and trends, Yvonne Man and Stephen Engle give global investors unique insight, delivering in-depth discussions with the newsmakers who matter. (Source: Bloomberg)
BING-JHEN HONG/iStock Editorial via Getty Images ASE Technology ( ASX ) reported unaudited consolidated net revenues of US$2B for May, up +2.2% from April and +26.1% year-over-year. ATM assembly, testing, and material business accounted for ~$1.34B (+35.2% Y/Y) of the revenue. More on ASE Technology ASE Technology: No Longer Just An OSAT, The LEAP Ramp Changes Everything ASE Technology: The Advanc...
BING-JHEN HONG/iStock Editorial via Getty Images ASE Technology ( ASX ) reported unaudited consolidated net revenues of US$2B for May, up +2.2% from April and +26.1% year-over-year. ATM assembly, testing, and material business accounted for ~$1.34B (+35.2% Y/Y) of the revenue. More on ASE Technology ASE Technology: No Longer Just An OSAT, The LEAP Ramp Changes Everything ASE Technology: The Advanced Packaging Story Is Believable, But The Valuation Might Be Stretched ASE Technology Holding Co., Ltd. (ASX) Q1 2026 Earnings Call Transcript Looking for under-the-radar value in the AI supply chain Foreign IT's strongest Quant picks are almost all semiconductors